We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-4 of 4

Federal Circuit confirms that generic ANDA applications did not infringe drug patents
  • Shook Hardy & Bacon LLP
  • USA
  • February 16 2012

The Federal Circuit Court of Appeals has determined that when generic drug makers seek Abbreviated New Drug Applications (ANDAs) from the Food and Drug Administration (FDA) for uses of patented drugs not covered by the patents, the generics do not infringe the patents.

Patentability of medical treatment claims to be heard by U.S. Supreme Court
  • Shook Hardy & Bacon LLP
  • USA
  • June 30 2011

The U.S. Supreme Court has agreed to review a Federal Circuit Court of Appeals ruling that methods for determining the optimal dosage of thiopurine drugs used to treat gastrointestinal and non-gastrointestinal autoimmune diseases recite patentable subject matter under 35 U.S.C. 101.

Madeleine M. McDonough
  • Shook Hardy & Bacon LLP